Invest with confidence in Sphere Fluidics – a trusted leader in the biopharmaceutical and cell therapy markets. Our prestigious history as a Cambridge University spin-out combined with our passionate and knowledgeable management team puts us in a unique position to excel in the Life Sciences tools market.
With a proven track record of over 400 international customers, £41 million in investment, and a portfolio of 135 international patents, we’re poised for rapid growth and profitability. Our novel picodroplet-based technologies fill a gap in the market, offering superior ROI with low risk.
We strive to meet consumer needs and develop products that allow our customers to find, analyze and isolate their most valuable cells, with ease and speed. Building on the success of our flagship Cyto-Mine® platform, we’re continuing to invest in our people, our facilities, and product development to successfully integrate cell biology, microfluidics, and cutting-edge engineering into groundbreaking solutions.
We understand the dynamic nature of the industry we serve. Our leaders are constantly looking for new opportunities and key growth markets to move into as part of our iterated strategy, built to minimize risk and maximize opportunity.
Join us at this pivotal point in our development as we continue to scale up and globalize our business.
